

Special Issue

Personalized Medicine in Kidney Transplantation and Immunology

Message from the Guest Editor

Transplantation has been the most potent and successful driver to study the immune system and the genetic individuality of HLA. These discoveries have led to clinical application of transplantation, saving life of patients affected by terminal organ failure. Organ transplantation has also driven the development of immunosuppressive agents to control activation of the immune system. Today, renal transplantation is the best treatment available for patients with end stage renal disease. Personalized medicine is today one of the most important task of modern medicine, and it is absolutely clear that transplantation, by its nature, is the best examples of applied personalized medicine, as we personalize organ allocation and the immunosuppressive strategy in our patients. We are inviting you to participate in this discussion on personalized medicine, submitting your personal experience or personal view to be published in the special number of *Journal of Personalized Medicine* dedicated to "Renal transplantation and immunology".

Guest Editor

Dr. Franco Citterio

Associate Professor, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Foggia, Italy

Deadline for manuscript submissions

closed (25 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed




mdpi.com/si/86313

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).